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Purpose: gammaD-Crystallin (CRYGD) is a major structural lens crystallin and its mutations result in congenital cataract
formation. In this study, we attempted to correct the altered protein features of G165fsX8 CRYGD protein with small
chemical molecules.
Methods: Recombinant FLAG-tagged mutants (R15C, R15S, P24T, R61C, and G165fsX8) of CRYGD were expressed
in COS-7 cells and treated with small chemical molecules with reported protein chaperoning properties (sodium 4-
phenylbutyrate [4-PBA], trimethylamine N-oxide [TMAO], and glycerol and DMSO [DMSO]). Protein solubility in 0.5%
Triton X-100 and subcellular distribution was examined by western blotting and immunofluorescence, respectively.
Apoptosis was assayed as the percentage of fragmented nuclei in transfected cells. Expression of heat-shock proteins
(Hsp70 and Hsp90) was examined by reverse transcription-polymerase chain reaction analysis.
Results: Unlike WT and most mutants (R15C, R15S, P24T, and R61C) of CRYGD, G165fsX8 CRYGD was significantly
insoluble in 0.5% Triton X-100. This insolubility was alleviated by dose-dependent 4-PBA treatment. The treatment
relieved the mislocalization of G165fsX8 CRYGD from the nuclear envelope. Also, 4-PBA treatment reduced cell
apoptosis and caused an upregulation of Hsp70.
Conclusions: 4-PBA treatment reduced the defective phenotype of mutant G165fsX8 CRYGD and rescued the affected
cells from apoptosis. This could be a potential treatment for lens structural protein and prevent lens opacity in cataract
formation.
Protein  aggregation  and  mistrafficking  characterize
many human disorders [1,2]. Protein folding to a native and
functionally active state is often assisted by the concentrated
milieu  of  cellular  environment  and  folding  machinery,
including  enzymes,  molecular  chaperones,  pH  regulators,
ions and transporters as well as input of metabolic energy
[3,4]. Conversely, they may misfold or unfold under stress
conditions,  including  aging,  pH/ion  or  temperature
fluctuation, and genetic mutation. Protein quality control is a
housekeeping  machinery  to  correct  aberrant  proteins  for
proper  folding  or  remove  them  through  endoplasmic
reticulum-associated  degradation  (ERAD)  [5-8].  When
protein folding stress overwhelms the protective action of
quality  control,  aggregation  could  occur  [9-11],  which  is
recognized as a major cause of different pathological diseases.
This  not  only  confers  loss-of-function,  but  also  gain-of-
function  proteotoxicity  or  cytotoxicity.  Mistrafficking  of
proteins  could  also  trigger  organelle  instability  or  even
dysfunction.
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Recently,  we  identified  G165fsX8  γD-crystallin
(CRYGD)  as  a  cause  of  congenital  nuclear  cataract  in  a
Chinese family [12]. CRYGD is a structural protein essential
for lens transparency. It exists as a highly symmetric monomer
with  four  Greek  key  motifs  organized  into  two  highly
homologous  β-sheets  connected  by  a  six-residue  linker.
Premature truncated G165fsX8 mutation removed the last β-
strand of the 4th Greek key motif and deleted Val170, a crucial
interdomain  residue  for  the  intrinsic  stability  of  native
CRYGD. Hence, the mutant protein was prone to precipitate
and loss of solubility. With the transfection in COS-7 cells,
G165fsX8  CRYGD  was  misolocalized  to  the  nuclear
envelope,  suggesting  an  impairment  to  the  nuclear
transfiguration in lens fiber cell differentiation, leading to
opacity development [12]. Moreover, the transfected cells
underwent apoptosis, which could also associate with lens cell
defects in cataract formation. In this study, we tested if the
mutant features and cellular defects could be amended by a
small molecule chemical with chaperoning activity. Our result
demonstrated  a  potential  correction  of  mutated  structural
protein with a folding problem.
METHODS
Expression  constructs  and  mutagenesis:  pFLAG/myc-
CRYGDWT  and  pFLAG-CRYGDG165fs  was  prepared  and
sequences were confirmed previously [12]. Other CRYGD
variant expression constructs were prepared and sequences
were confirmed [13].
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997Cell culture and transfection: COS-7 cells (American Tissue
Culture  Collection,  Manassas,  VA)  were  maintained  in
Eagle’s  Minimal  Essential  medium  (Invitrogen,  Carlsbad,
CA)  with  10%  fetal  bovine  serum  (FBS;  Invitrogen)  and
antibiotics.  Prior  to  transfection,  negligible  endogenous
CRYGD mRNA and protein of COS-7 cells was verified by
reverse transcription-polymerase chain reaction (RT–PCR)
and western blotting, respectively [12]. Cells (105 cells/cm2)
were transfected with CRYGD constructs by using FuGene
HD reagent (Roche, Basel, Switzerland) at a ratio of 3 μl
FuGene per μg DNA in Opti-MEM®I (Invitrogen). Chemical
chaperone treatments were started 24 h after transfection.
Treatment by chemical chaperones: Sodium 4-phenylbutyrate
(4-PBA, 0.25 to 3 mM, triButyrate; Triple Crown America
Inc., Perkasie, PA), trimethylamine N-oxide (TMAO, 25 to
300 mM; Sigma, 
St. Louis, MO), glycerol (1 to 5%; Sigma) or DMSO (DMSO,
0.5 to 1%; Sigma) was added to the transfected cell culture.
Fresh medium containing drugs was replenished every two
days.
Triton X-100 (Tx) solubility analysis: Cells were washed with
ice-cold PBS and added with lysis buffer with 100 mM Tris-
HCl (pH 7.4), 3 mM EGTA (Sigma), 5 mM MgCl2, 0.5% Tx
(Sigma),  protease  inhibitor  cocktail  (Roche)  and
phenylmethylsulfonylfluoride 1 mM (PMSF; Sigma) for 2
min on ice. After centrifugation, clear supernatant containing
Tx-soluble  protein  was  denatured  in  buffer  with  2%  Na
dodecylsulfate  (SDS)  and  50  mM  DL-dithiothreitol  (DTT;
Sigma).  The  pellet  containing  Tx-insoluble  protein  was
washed twice with ice-cold PBS, sonicated, and denatured in
9 M urea-SDS buffer. The samples were analyzed with SDS–
PAGE  and  western  blotting  using  horseradish  peroxidase
(HRP)-conjugated  antibodies  against  FLAG  (recognizing
CRYGD),  glyceraldehyde  3-phosphate  dehydrogenase
(GAPDH),  or  β-actin  (Sigma),  followed  by  enhanced
chemiluminescence (ECL; GE Healthcare, Pittsburgh, PA).
Band intensity was analyzed by Quantity One Image Analysis
4.6.2  (BioRad,  Hercules,  CA).  FLAG  expression  was
normalized with GAPDH for Tx-soluble protein and β-actin
for  Tx-insoluble  protein.  Statistical  significance  was
determined by independent Student’s t test.
Immunofluorescence:  Cells  were  fixed  with  2%  neutral
buffered  paraformaldehyde  in  PBS,  permeabilized  and
detected  with  mouse  monoclonal  anti-FLAG  (recognizing
CRYGD;  Sigma)  followed  by  appropriate  fluorescence
conjugated  IgG  secondary  antibody  (Jackson  ImmunoRes
Lab, West Gloves, PA) and DAPI (Sigma) staining.
Transcription  analysis:  Total  RNA  was  purified  using  a
RNeasy kit (Qiagen, Valencia, CA) and an on-column RNase-
free DNase kit (Qiagen). cDNA from 1 μg RNA, 10 ng/ml
random  hexanucleotide  primer  (Invitrogen)  and  reverse
transcriptase (SuperScript III; Invitrogen) was amplified for
heat-shock  proteins,  Hsp70  (forward:  5'-AAG  TAC  AAA
GCG GAG GAC G-3', reverse: 5'-GAT GGG GTT ACA CAC
CTG C-3'), Hsp90 (forward: 5'-ACC CAG ACC CAA GAC
CAA CCG-3', reverse: 5'-ATT TGA AAT GAG CTC TCT
CAG-3') and housekeeping GAPDH (forward: 5'-GAA GGT
GAA GGT CGG AGT-3', reverse: 5'-GAA GAT GGT GAT
GGG  ATT  TC-3').  After  agarose  gel  electrophoresis,  the
specific band intensity was analyzed and normalized with
housekeeping  GAPDH  expression.  Statistical  significance
was assayed using independent Student’s t test.
Terminal apoptosis assay: Paraformaldehyde-fixed cells were
stained for FLAG and red X-conjugated secondary antibody
and  nuclei  counterstained  with  DAPI.  Samples  were
examined  by  fluorescence  microscopy  (DMRB;  Leica,
Wetzlar, Germany) equipped with a color imaging system
(Spot  RT;  Diagnostic  Instruments,  Sterling  Heights,  MI).
Terminal apoptosis rate was represented as the percentage of
cells with fragmented nuclei. For each experiment (n=3), 10
random images (40× objective) were analyzed.
RESULTS
4-PBA improved the solubility of G165fsX8 CRYGD: The
expected molecular size of FLAG/myc-tagged WT CRYGD
was ~28 kDa and the size of truncated FLAG-tagged G165fs
CRYGD (a shorten peptide and without myc) was ~24 kDa.
We first confirmed our previous finding of the reduced Tx
solubility  of  G165fsX8  CRYGD  mutant  in  COS-7  cells
(Figure  1).  After  western  blotting  of  FLAG  (representing
CRYGD)  followed  by  band  densitometry  analysis,  we
observed about 83% of truncated FLAG-tagged G165fsX8
CRYGD  (~24  kDa)  present  in  the  Tx-insoluble  fraction,
whereas  less  than  5%  FLAG/myc-tagged  WT  CRYGD
(~28 kDa) was Tx-insoluble (Figure 2A) [12]. At one-day
post-transfection, we started treating the cells with chemical
chaperone 4-PBA (from 0.25 to 3 mM) for two days, followed
by  cell  collection  for  Tx  solubility  assay.  A  dose-related
change of Tx solubility of G165fsX8 mutant was observed
(Figure  1A,B).  Experiments  were  done  in  triplicate  and
treatment with 4-PBA from 1 to 3 mM caused a significant
reduction of mean Tx insolubility to 37% (for 1 mM 4-PBA),
15% (2 mM 4-PBA) and 10% (3 mM 4-PBA), when compared
to  83%  of  the  untreated  samples  (p<0.05,  independent
Student’s  t-test).  Simultaneously,  the  amount  of  mutant
protein  in  Tx  soluble  fractions  increased  proportionally
(Figure 1B).
To  validate  this  effect  on  other  reported  chemical
chaperones, we treated the transfected cells in TMAO (from
25 to 200 mM) for 2 days but the results did not show any
correction of Tx solubility (Figure 1C,D). Treatment with
DMSO (0.5 to 1%) or glycerol (1 to 5%) was also ineffective
in improving mutant solubility and cytotoxicity was observed
(not shown). We confirmed that 4-PBA was more effective in
lowering the amount of insoluble G165fsX8 GRYGD, to a
level similar to that of WT protein.
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9984-PBA improved the solubility of different CRYGD mutants:
To test if 4-PBA also improved the solubility of other reported
cataract-causing CRYGD mutants (R15C, R15S, P24T and
R61C), we created recombinant FLAG/myc-tagged CRYGD
mutants by PCR-based site-directed mutagenesis and these
constructs  were  confirmed  by  direct  sequencing.  These
missense  mutants  with  FLAG  and  myc  tagging  have  an
expected molecular size of ~28 kDa. An appreciable amount
of mutant proteins were Tx-insoluble but the percentages were
lower than that of G165fsX8 mutant (Tx insolubility of R15C:
17%, R15S: 15%, P24T: 14%, and R61C: 19%, compared to
83%  for  G165fsX8  and  5%  for  WT  protein;  Figure  2A).
Following 4-PBA (1 mM) treatment for two days, the Tx
insolubility of these missense mutants was reduced and most
mutant protein became predominantly Tx-soluble (Figure 2).
Only faint detection was noted in the Tx insoluble fractions.
The reduction of G165fsX8 insolubility in 0.5% Tx was again
noted after 4-PBA treatment.
4-PBA  relocalized  G165fs  CRYGD  from  the  nuclear
envelope:  When  expressed  in  COS-7  cells,  G165fsX8
CRYGD was redistributed as a ring-shaped structure on the
nuclear  periphery  (Figure  3C).  Minimal  staining  in  the
cytoplasm  and  inner  nucleus  was  observed.  Our  previous
confocal microscopy study identified its colocalization with
lamin  A/C  in  the  nuclear  envelope  [12].  In  contrast,  WT
CRYGD was located in both nuclear and cytoplasmic regions
Figure 1. Chemical chaperone 4-PBA
improved  Tx  solubility  of  G165fsX8
CRYGD  expressing  in  COS-7  cells.
Cells were treated with 4-PBA (0 to 3
mM) for two days followed by western
blotting for FLAG-tagged CRYGD and
band  densitometry  (represented  by
histogram). A: Tx insoluble fractions.
B:  Tx  soluble  fractions.  β-Actin  and
GAPDH  were  the  housekeeping
proteins  of  Tx-insoluble  and  soluble
fractions,  respectively.  Asterisks
indicate  a  p<0.05  by  independent
Student’s t-test. C: Treatment of cells
with TMAO (0 to 300 mM) for two days
followed  by  Tx  solubility  test  for
FLAG-tagged CRYGD expression. D:
Band densitometry analysis showed that
TMAO did not affect the mutant protein
solubility.
Figure 2. 4-PBA improved the solubility
of  various  cataract-causing  CRYGD
mutants expressing in COS-7 cells. A:
western  blotting  of  FLAG  and
housekeeping proteins in Tx soluble and
insoluble  fractions  from  cells
expressing  WT,  R15C,  R15S,  P24T,
R61C,  or  G165fsX8  CRYGD  treated
(right) or not (left) with 1 mM 4-PBA
for two days. B: Band densitometry of
FLAG-tagged  CRYGD  normalized
with  housekeeping  proteins  in  cells
from A. Asterisk indicated a p<0.05 by
independent Student’s t-test.
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999(Figure 3A). This was different from the reported cytoplasmic
staining of normal CRYGD and this could be due to the
protein overexpression by cytomegalovirus (CMV) promoter.
We focused our observation on the defective nuclear envelope
staining of mutant CRYGD. Treatment with 4-PBA (1 mM)
for five days successfully reduced the mutant cells showing
CRYGD on the nuclear envelope. Instead, most treated cells
exhibited  nuclear  and  faint  cytoplasmic  CRYGD  staining
(Figure 3D). A quantitative analysis by counting a minimum
of 200 trasnsfected cells in triplicated experiments showed
that 20% of mutant cells were devoid of nuclear envelope
staining of CRYGD after 0.5 mM 4-PBA treatment and 60%
after 1 mM 4-PBA treatment. No change was found for WT
CRYGD-expressing cells treated or not with 4-PBA (Figure
1A,B).
4-PBA rescued G165fsX8 mutant cells from apoptosis: In the
same  cell  preparation  and  treatment,  we  quantified  the
apoptosis  rate  by  the  percentage  of  G165fsX8  CRYGD-
expressing cells (FLAG-positive) showing fragmented nuclei
upon DAPI staining. In untreated cells, the apoptosis rate was
~13%, which was about threefold higher than that of WT cells
(4%;  p<0.05,  independent  Student’s  t-test;  Figure  3E).
Treatment with 1 mM PBA for five days significantly reduced
the apoptosis rate to ~6% (p<0.05, independent Student’s t-
test). There was no clear difference in the apoptosis rate of
WT cells with or without 4-PBA treatment (Figure 3E).
4-PBA upregulated Hsp70 expression: We hypothesized that
the correction of G165fsX8 CRYGD for greater solubility
could be mediated through heat-shock responses initiated by
4-PBA. By RT–PCR analysis, the steady-state Hsp70 and
Hsp90 expressions were investigated. Each experiment was
done  in  triplicate  and  GAPDH  amplification  was  the
housekeeping control and normalization. We detected Hsp70
upregulation in mutant cells after 1 mM 4-PBA treatment
(p<0.05,  independent  Student’s  t-test;  Figure  3F),  but  no
change of Hsp90 expression was observed.
DISCUSSION
γD-Crystallin (CRYGD) is a lens structural protein and its
mutations are known to cause different types of congenital
cataracts [12-16]. In this study, we studied different cataract-
causing  CRYGD  mutants  in  vitro.  While  WT  and  most
CRYGD mutants were mildly insoluble upon Tx extraction,
G165fsX8 mutant demonstrated significant Tx insolubility.
Unlike  WT  CRYGD,  G165fsX8  was  mislocalized  to  the
nuclear  envelope  which  was  consistent  with  our  previous
report on its colocalization with lamin A/C [12]. Our present
work attempted to rescue the disrupted features by treatment
with  small  molecule  chemicals  with  reported  protein
chaperoning activity. While TMAO, DMSO, and glycerol
were  not  effective,  4-PBA  was  shown  to  reduce  the  Tx
insolubility  of  G165fsX8  mutant  dose-dependently  and
Figure 3. The corrective effect of 4-PBA
on G165fsX8-expressing cells. A-D: 4-
PBA  corrected  the  mislocalization  of
G165fs CRYGD as shown by confocal
immunofluorescence. A: Untreated WT
cells and B: WT cells treated with 1 mM
PBA for two days. C: Untreated G165fs
CRYGD cells and D: G165fs CRYGD
cells treated with 1 mM PBA for two
days. E: 4-PBA reduced apoptosis of
mutant cells with nuclear fragmentation.
The  asterisk  indicates  a  p<0.05  by
independent Student’s t-test. F: Semi-
quantitative RT–PCR analysis showed
specific  upregulation  of  Hsp70  in
G165fs CRYGD cells treated with 4-
PBA (p<0.05, independent Student’s t-
test). No significant change was found
for Hsp90.
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1000removed  its  localization  from  the  nuclear  envelope.  This
reduced the number of cells undergoing apoptosis. We also
demonstrated upregulation of Hsp70, which could be involved
in cell rescue.
Our study stated a proof-of-principle correction of lens
CRYGD by 4-PBA to regain proper cellular features. This can
be of therapeutic potential to alleviate, in our case congenital
cataracts  or,  aggregopathies  due  to  defective  structural
proteins.  Chemical  chaperoning  has  been  shown
experimentally to correct protein’s non-native conformation,
mistrafficking and the associated cellular defects, resulting in
cell survival [17-20]. Though the exact mechanisms are not
well defined, chemical chaperones likely shift the folding
equilibrium toward more native states, reduce non-productive
aggregation  or  enhance  the  resident  chaperoning
environment. This improves protein folding and facilitates the
transport  of  proteins  across  intracellular  compartments.
Increasing  evidence  has  rendered  the  chaperone-assisted
protein  rescue  an  appealing  strategy  for  protein  folding
disease management [21-34].
4-PBA is known as a peroxisome proliferator and histone
deacetylase  inhibitor  to  affect  transcription  [35-37].  It  is
approved for clinical use to restore chloride conductance in
cystic fibrosis patients and treat urea cycle disorders [38-40].
No  drug-induced  toxicity  was  encountered  by  patients.
Functioning  as  a  chemical  chaperone,  it  significantly
improves the folding of different proteins, like α1-antitrypsin,
nephrin,  myocilin,  Pael  receptor  and  restores  protein
localization and cell viability [22,27,41,42]. The molecular
mechanism  of  how  4-PBA  recovers  protein  appears
inconclusive. Though it has been reported as a transcriptional
regulator, no significant gene changes were observed for the
ER  unfolded  protein  response  [43].  In  contrast,  down-
regulation  of  constitutive  Hsc70  protein  caused  by  the
decreased stability of mRNA was observed, indicating a mode
of action different from that of inhibiting deacetylase activity
[44]. In our assay, we found an inducible Hsp70 expression
after 4-PBA treatment. This could be beneficial for protein
disaggregation,  protein  folding  and  complex  remodeling,
trafficking and regulation of heat-shock responses [45-49].
However,  the  role  of  Hsp70  in  the  folding  of  structural
proteins is unknown, except the co-staining of Hsp70 with
misfolded keratin in Mallory bodies [50]. Interaction of small
Hsp47  with  type  I  collagen  was  important  for  the  Golgi
transport  [51,52].  Moreover,  Hsp70  is  anti-apoptotic  by
directly associating with Apaf-1, by antagonism of apoptosis-
inducing factor, or through direct suppression of downstream
caspases [53,54]. Inhibition of its function is sufficient to
induce  cell  death  in  some  tumors  [55].  In  zebrafish  lens
development, inducible Hsp70 is a vital regulator for lens fiber
cell differentiation [56,57].
The result of 4-PBA correction of cells with G165fsX8
CRYGD was similar to that previously described for TMAO
on G98R CRYAA [31]. However, TMAO was not effective
for G165fsX8 CRYGD-expressing cells, the same as for 4-
PBA  on  cells  with  G98R  CRYAA.  This  indicates  that
mutations of different crystallin molecules may have specific
chaperone treatments with unknown mechanisms. Though
Hsp70 was upregulated after both treatments, TMAO has an
additional role on the hydration energy in the protein folding
process [58]. The presence of exposed hydrophobic patches
in G98R CRYAA could thus be modified or removed by
TMAO, resulting in a more stabilized conformation [31].
In  conclusion,  4-PBA  reversed  the  defective  cellular
features caused by G165fsX8 CRYGD and reduced apoptosis
possibly through initiation of heat shock response. Hsp70
upregulation could be caused by 4-PBA directly or a change
of chaperoning capacity in cells. It could be a consequence of
mutant protein stabilization. Further work warrants a better
characterization of Hsp70 regulation in cataractogenesis and
for potential therapeutic strategy.
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